ATP Life Science Ventures L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-06-28 8:56 pm Sale | 2021-06-21 | 13D | Akero Therapeutics, Inc. AKRO | ATP Life Science Ventures L.P. | 674,640 1.900% | -5,164,229 (-88.45%) | Filing |
| 2020-07-14 5:06 pm Purchase | 2020-07-10 | 13D | Akero Therapeutics, Inc. AKRO | ATP Life Science Ventures L.P. | 5,838,869 17.200% | 423,666 (+7.82%) | Filing |